Paper Details

  1. Home
  2. Paper Details

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.

Author: BattiatoKristen, DorseyColleen, FalchiLorenzo, FalcoVictoria, FeldmanTatyana A, FoxYehudit, KdirySabrina, LaudatiCarissa, LebowitzSonia, LeslieLori A, MartignettiRosalba, MatoAnthony R, McCarthyElizabeth, MiskinHari P, PantonGail, ParkJae H, PaskalisDana, Pena VelasquezCamila, PurdomMichelle, RoekerLindsey E, SoumeraiJacob D, SportelliPeter, StrausDavid J, ThompsonMeghan C, TurpuseemaTeja, ZelenetzAndrew D

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Ibrutinib is a transformative treatment for chronic lymphocytic leukemia (CLL), but its effectiveness is limited by toxicity and resistance. This study explores the use of an "add-on" approach with umbralisib and ublituximab in patients with detectable MRD, aiming to achieve undetectable-MRD and potentially allowing for treatment-free observation periods.
Paper Details　
Original Abstract of the Article :
Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35852793

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: Exploring Novel Treatment Strategies

The treatment landscape for [chronic lymphocytic leukemia (CLL)] is continually evolving, with new therapies emerging to address the challenges of [toxicity and resistance] to existing medications. This study investigates a novel [add-on approach] for patients with CLL who have [detectable minimal residual disease (MRD)] after treatment with [ibrutinib]. The authors employed [a phase II clinical trial] to evaluate the efficacy of adding [umbralsib and ublituximab (U2)] to ibrutinib, followed by a period of [treatment-free observation (TFO)]. Their findings offer insights into the potential of this combination therapy to achieve [undetectable MRD (U-MRD)] and improve outcomes for patients with CLL.

A Promising Combination Therapy for CLL: Addressing MRD and Achieving Remission

The study demonstrates the potential of [adding umbralsib and ublituximab to ibrutinib] to achieve [U-MRD] in patients with CLL. This approach offers a promising strategy for [deepening remission] and potentially improving long-term outcomes for patients with CLL. The authors emphasize the need for [further investigation] to confirm the efficacy and safety of this combination therapy.

Navigating the Treatment Landscape of CLL: Tailoring Therapy to Individual Needs

This study highlights the importance of [individualizing treatment plans] for patients with CLL, considering factors such as [MRD status, prior therapies, and patient-specific characteristics]. The authors emphasize the crucial role of [ongoing research] to develop and evaluate new treatment strategies that address the unique challenges of CLL, leading to improved outcomes for patients.

Dr. Camel's Conclusion

Imagine a desert oasis where a rare and precious pearl represents the elusive goal of achieving U-MRD in CLL patients. This study explores a new approach, like a skilled desert guide, to navigate the complexities of CLL treatment and guide patients towards a path of deeper remission and improved well-being.

Date :
  1. Date Completed 2022-09-16
  2. Date Revised 2023-03-17
Further Info :

Pubmed ID

35852793

DOI: Digital Object Identifier

NIHMS1826131

Related Literature

Article Analysis
・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.